PMID- 17089056
OWN - NLM
STAT- MEDLINE
DCOM- 20061228
LR  - 20061107
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 16
IP  - 6
DP  - 2006 Dec
TI  - Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T 
      lymphocytes against murine colon cancer: a comparative analysis of antigen 
      loading methods for the vaccination of immunotherapeutic dendritic cells.
PG  - 1317-24
AB  - Dendritic cells (DCs) have been used successfully for inducing effective 
      anti-tumor immune responses in advanced cancer patients undergoing tumor-specific 
      immunotherapy. Appropriate antigen pulsing is a crucial parameter for optimizing 
      the efficacy of immunotherapy as well as anti-tumor protection therapy. Using a 
      murine colon cancer model, we evaluated the anti-tumor efficacy of four different 
      preparations of DC vaccines that contained either a whole tumor or its 
      derivatives, including i) DCs pulsed with tumor lysate, ii) DCs pulsed with 
      necrotic tumor cells, iii) DCs pulsed with apoptotic tumor cells, and iv) 
      DC-tumor cell fusion hybrids. Our data show that DC-tumor cell fusion hybrids and 
      DCs pulsed with irradiated apoptotic tumor cells were more potent than DCs with 
      freeze-thawed necrotic tumor cells for the induction of protective anti-tumor 
      responses. The vaccination of DCs pulsed with tumor lysate failed to elicit any 
      anti-tumor effect. In animals administered with higher doses of a tumor-cell 
      challenge, DC-tumor cell fusion hybrids elicited the most effective anti-tumor 
      response. Among the preparations tested, mice immunized with DC-tumor cell fusion 
      hybrids resulted in the greatest induction of cytotoxicity as measured by the 
      cytotoxic T lymphocyte activity of both the splenocytes and the Thy1.2-positive T 
      lymphocytes. Furthermore, the in vitro production of IFN-gamma polarized to the 
      Th1 cytokine responses was highest in the splenocytes derived from mice 
      vaccinated with DC-tumor cell fusion hybrids. Our results suggest that DC-tumor 
      cell fusion hybrids are more potent inducers of protection against solid tumors, 
      such as colon cancer, than other antigen-loading strategies using whole tumor 
      cell materials.
FAU - Yasuda, Takashi
AU  - Yasuda T
AD  - Department of Gastroenterological Surgery, Graduate School of Medical Sciences, 
      Kobe University, Kobe 650-0017, Japan.
FAU - Kamigaki, Takashi
AU  - Kamigaki T
FAU - Nakamura, Tetsu
AU  - Nakamura T
FAU - Imanishi, Tatsuya
AU  - Imanishi T
FAU - Hayashi, Shun
AU  - Hayashi S
FAU - Kawasaki, Kentaro
AU  - Kawasaki K
FAU - Takase, Shiro
AU  - Takase S
FAU - Ajiki, Tetsuo
AU  - Ajiki T
FAU - Kuroda, Yoshikazu
AU  - Kuroda Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cell Extracts)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - Apoptosis/physiology
MH  - Cancer Vaccines/*immunology
MH  - Cell Extracts/immunology
MH  - Cell Fusion
MH  - Colonic Neoplasms/immunology/*therapy
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Hybrid Cells
MH  - Immunotherapy/*methods
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Necrosis/physiopathology
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2006/11/08 09:00
MHDA- 2006/12/29 09:00
CRDT- 2006/11/08 09:00
PHST- 2006/11/08 09:00 [pubmed]
PHST- 2006/12/29 09:00 [medline]
PHST- 2006/11/08 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2006 Dec;16(6):1317-24.